Kiniksa Pharmaceuticals Reports Third Quarter 2021 Financial Results and Recent Portfolio Execution
01. November 2021 08:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
- Q3 2021 ARCALYST® (rilonacept) net revenue of $12.1 million -- ARCALYST prescribed by more than 200 physicians for recurrent pericarditis since approval -- Data from Phase 3 trial of mavrilimumab in...
Kiniksa Pharmaceuticals to Report Third Quarter 2021 Financial Results on November 1, 2021
29. Oktober 2021 16:01 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Oct. 29, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Monday, November 1, 2021, at...
Kiniksa Pharmaceuticals to Present at 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
21. September 2021 16:01 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 2021 Cantor Fitzgerald Virtual Global Healthcare...
Kiniksa Announces Launch of ARCALYST Named Patient Program
16. August 2021 08:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
- Named Patient Program supports patient access to ARCALYST® (rilonacept) in countries where ARCALYST is not currently commercially available - HAMILTON, Bermuda, Aug. 16, 2021 (GLOBE NEWSWIRE)...
Kiniksa Reports Second Quarter 2021 Financial Results and Recent Corporate and Portfolio Activity
03. August 2021 08:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
- Q2 2021 ARCALYST® (rilonacept) net revenue of $7.7 million with greater than 100 prescribing physicians - - Phase 3 data from mavrilimumab clinical trial in COVID-19-related ARDS on-track for Q1...
Kiniksa Pharmaceuticals to Present at 2021 Wedbush PacGrow Healthcare Conference
02. August 2021 16:01 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 2021 Wedbush PacGrow Healthcare Conference on Tuesday,...
Kiniksa Pharmaceuticals to Report Second Quarter 2021 Financial Results on August 3, 2021
20. Juli 2021 16:01 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, July 20, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, August 3, 2021 at...
Kiniksa Announces Issuance of U.S. Patent for Treatment of Recurrent Pericarditis
08. Juni 2021 16:01 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, June 08, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a portfolio of assets designed to modulate...
Kiniksa Outlines Next Steps for the Development of Mavrilimumab
08. Juni 2021 07:30 ET
|
Kiniksa Pharmaceuticals, Ltd.
- Defined regulatory pathway for Phase 3 clinical development of mavrilimumab in multiple indications - - Continued development in COVID-19-related ARDS represents fastest path to potential...
Kiniksa Pharmaceuticals to Present at Goldman Sachs 42nd Annual Global Healthcare Conference
01. Juni 2021 16:01 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, June 01, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the Goldman Sachs 42nd Annual Global Healthcare...